PYXIS ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.3 USD | 0.00% |
|
+3.37% | +138.89% |
| Mar. 22 | H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating | MT |
| Mar. 21 | Health Care Up on Drug Sales Optimism -- Health Care Roundup | DJ |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 353.3 | 46.7 | 79.75 | 250 | - | - |
| Enterprise Value (EV) 1 | 78.6 | -134.1 | 79.75 | 250 | 250 | 250 |
| P/E ratio | -4.74 x | -0.37 x | -0.97 x | -5.63 x | -3.37 x | -3.19 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 55.5 x | 500 x | 27.8 x |
| EV / Revenue | - | - | - | 55.5 x | 500 x | 27.8 x |
| EV / EBITDA | -5,115,596 x | -380,378 x | - | - | - | - |
| EV / FCF | -9,851,510 x | -487,808 x | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - |
| Price to Book | 1.38 x | 0.29 x | - | - | - | - |
| Nbr of stocks (in thousands) | 32,209 | 34,851 | 44,304 | 58,133 | - | - |
| Reference price 2 | 10.97 | 1.340 | 1.800 | 4.300 | 4.300 | 4.300 |
| Announcement Date | 3/29/22 | 3/22/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 4.5 | 0.5 | 9 |
| EBITDA | - | -69.07 | -122.8 | - | - | - | - |
| EBIT 1 | - | -69.72 | -123.5 | -82.2 | -67.99 | -80.12 | -100.4 |
| Operating Margin | - | - | - | - | -1,510.89% | -16,024.5% | -1,115.42% |
| Earnings before Tax (EBT) 1 | - | -75.98 | -120.7 | -73.79 | -43.14 | -75.71 | -99 |
| Net income 1 | -12.83 | -75.98 | -120.7 | -73.79 | -43.14 | -75.71 | -99 |
| Net margin | - | - | - | - | -958.56% | -15,142.67% | -1,100.01% |
| EPS 2 | -1.960 | -2.313 | -3.650 | -1.850 | -0.7633 | -1.277 | -1.350 |
| Free Cash Flow | - | -35.87 | -95.73 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 6/21/21 | 3/29/22 | 3/22/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | 4.125 | 0.125 | 0.125 | 0.125 | 0.5 |
| EBITDA | - | -16.27 | -31.23 | -25.57 | -28.19 | -37.78 | - | -17.6 | - | - | - | - | - | - | - |
| EBIT 1 | -11.62 | -16.43 | -31.39 | -25.73 | -28.39 | -37.97 | -20.95 | -18.12 | -25.35 | -17.77 | -13.38 | -18.06 | -18.44 | -18.36 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | -324.35% | -14,448.6% | -14,752.2% | -14,688% | - |
| Earnings before Tax (EBT) 1 | -14.18 | -16.83 | -31.38 | -25.56 | -27.67 | -36.1 | -19.24 | -15.9 | -23.05 | -15.6 | -10.37 | -13.18 | -10.17 | -9.745 | - |
| Net income 1 | -14.18 | -16.83 | -31.38 | -25.56 | -27.67 | -36.1 | -19.24 | -15.9 | -23.05 | -15.6 | -10.37 | -13.18 | -10.17 | -9.745 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | -251.44% | -10,546.94% | -8,133.86% | -7,796.26% | - |
| EPS 2 | -0.4470 | -0.5700 | -0.9700 | -0.7900 | -0.8500 | -1.040 | -0.5400 | -0.4100 | -0.5600 | -0.3300 | -0.1833 | -0.2267 | -0.1833 | -0.1733 | -0.3500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/29/22 | 5/13/22 | 8/15/22 | 11/1/22 | 3/22/23 | 5/11/23 | 8/11/23 | 11/7/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 275 | 181 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -35.9 | -95.7 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -61.9% | -57.2% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | 7.970 | 4.600 | - | - | - | - |
| Cash Flow per Share | - | -4.160 | -2.700 | - | - | - | - |
| Capex 1 | - | 0.54 | - | 6.73 | 1.5 | 1.75 | - |
| Capex / Sales | - | - | - | - | 33.33% | 350% | - |
| Announcement Date | 6/21/21 | 3/29/22 | 3/22/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.3
USD
Average target price
7.333
USD
Spread / Average Target
+70.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +138.89% | 250M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PYXS Stock
- Financials Pyxis Oncology, Inc.
